Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series

Evangelia Liakoni, Patrick C Dolder, Katharina M Rentsch, Matthias E Liechti, Evangelia Liakoni, Patrick C Dolder, Katharina M Rentsch, Matthias E Liechti

Abstract

Background: Although the recreational use of psychoactive substances is common there is only limited systematic collection of data on acute drug toxicity or hospital presentations, in particular regarding novel psychoactive substances (NPS) that have emerged on the illicit market in the last years.

Methods: We included all cases presenting at the emergency department (ED) of the University Hospital of Basel, Switzerland, between October 2014 and September 2015 with acute toxicity due to self-reported recreational drug use or with symptoms/signs consistent with acute toxicity. Intoxications were confirmed using immunoassays and LC-MS/MS, detecting also novel psychoactive substances.

Results: Among the 50'624 attendances at the ED, 210 were directly related to acute toxicity of recreational drugs. The mean patient age was 33 years and 73 % were male. Analytical drug confirmation was available in 136 cases. Most presentations were reportedly related to cocaine (33 %), cannabis (32 %), and heroin (14 %). The most commonly analytically detected substances were cannabis (33 %), cocaine (27 %), and opioids excluding methadone (19 %). There were only two NPS cases; a severe intoxication with paramethoxymethamphetamine (PMMA) in combination with other substances and an intoxication of minor severity with 2,5-dimethoxy-4-propylphenethylamine (2C-P). The most frequent symptoms were tachycardia (28 %), anxiety (23 %), nausea or vomiting (18 %), and agitation (17 %). Severe complications included two fatalities, two acute myocardial infarctions, seizures (13 cases), and psychosis (six cases). Most patients (76 %) were discharged home, 10 % were admitted to intensive care, and 2 % were referred to psychiatric care.

Conclusion: Most medical problems related to illicit drugs concerned cocaine and cannabis and mainly included sympathomimetic toxicity and/or psychiatric disorders confirming data from the prior year. Importantly, despite the dramatic increase in various NPS being detected in the last years, these substances were infrequently associated with ED presentations compared with classic recreational drugs.

Keywords: Acute toxicity; Psychoactive substances; Recreational drugs.

Figures

Fig. 1
Fig. 1
Self-reported substance use (count of cases)
Fig. 2
Fig. 2
Substances analytically confirmed (count of cases)

References

    1. European Drug Report 2015. Trends and developments: European Monitoring Centre for Drugs and Drug Addiction. Lisboa, Portugal: EMCDDA; 2015.
    1. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49(8):705–19. doi: 10.3109/15563650.2011.615318.
    1. Wood DM, Heyerdahl F, Yates CB, Dines AM, Giraudon I, Hovda KE, et al. The European Drug Emergencies Network (Euro-DEN) Clin Toxicol (Phila) 2014;52(4):239–41. doi: 10.3109/15563650.2014.898771.
    1. Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol (Phila) 2014;52(10):1005–12. doi: 10.3109/15563650.2014.976792.
    1. Liakoni E, Dolder PC, Rentsch K, Liecht ME. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. Swiss Med Wkly. 2015;145:w14166.
    1. Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Euro-DEN Research Group et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN) Clin Toxicol (Phila) 2015;53(9):893–900. doi: 10.3109/15563650.2015.1088157.
    1. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–13. doi: 10.3109/15563659809028940.
    1. Mueller DM, Rentsch KM. Online extraction toxicological MS(n) screening system for serum and heparinized plasma and comparison of screening results between plasma and urine in the context of clinical data. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883–884:189–97. doi: 10.1016/j.jchromb.2011.08.022.
    1. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32(1):1–28. doi: 10.1016/j.emc.2013.09.001.
    1. Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly. 2015;145:w14043.
    1. Vevelstad M, Øiestad EL, Middelkoop G, Hasvold I, Lilleng P, Delaveris GJ, et al. The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications. Forensic Sci Int. 2012;219(1–3):151–7. doi: 10.1016/j.forsciint.2011.12.014.
    1. Katzung BG, Masters SB, Trevor AJ. Basic & clinical pharmacology. 12. Lange: Mc Graw Hill Medical; 2012.
    1. Kupferschmidt H, Rauber-Lüthy C. Akute Vergiftungen. In: Schoenenberger RA, Haefeli WE, Schifferli J. Internistische Notfälle. 8th edition. Stuttgart, Germany: Thieme; 2008. p. 456–493.
    1. Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96(6):678–85. doi: 10.1093/bja/ael078.
    1. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18(5):228–45. doi: 10.1159/000337028.
    1. Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI. Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry. 2014;205(5):407–8. doi: 10.1192/bjp.bp.114.149252.
    1. de Guglielmo G, Cippitelli A, Somaini L, Gerra G, Li H, Stopponi S, et al. Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addict Biol. 2013;18(4):644–53. doi: 10.1111/j.1369-1600.2012.00468.x.
    1. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491–6. doi: 10.1007/s40263-014-0164-4.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever